Read this manager's filing book
Disclosed positions
Rhenman & Partners Asset Management AB: source evidence dated 2026-08-14T03:59:59.999Z.
- Issuer
- UNITED HEALTH GROUP INC
- Ticker
- UNH
- Class
- COM
- Reported value
- $38,902,968
- Reported amount
- 93,600
- Unit
- SH
- Option
- None
The displayed owner or issuer and source fields identify the receipt to verify; keep reporting and availability dates separate.
What was reported for this quarter?
13F positions are dated quarter-end holdings, with later publication and possible amendments. Read report period and availability before calling them current.
SEC 13F-HR: 0001213900-26-088652Open the effective filing receipt and inspect shares, value and any put/call classification separately.
Browse institutional filings
Open the effective filing receipt and inspect shares, value and any put/call classification separately.
Browse institutional filingsKeep reporting dates and units beside the answer, and inspect its original citations.
Disclosed positions
See the complete disclosed positions
| UNITED HEALTH GROUP INC | UNH | COM | $38,902,968 | 93,600 | SH | None |
| CVS HEALTH CORP | CVS | COM | $28,901,240 | 279,374 | SH | None |
| ASTRAZENECA PLC | AZN | ORD | $28,480,798 | 151,500 | SH | None |
| MERCK & CO INC | MRK | COM | $27,434,750 | 213,500 | SH | None |
| LILLY ELI & CO | LLY | COM | $26,765,280 | 22,315 | SH | None |
| ABBVIE INC | ABBV | COM | $24,352,461 | 96,775 | SH | None |
| ALIGNMENT HEALTHCARE INC | ALHC | COM | $23,740,546 | 997,083 | SH | None |
| EDWARDS LIFESCIENCES CORP | EW | COM | $23,519,600 | 260,000 | SH | None |
| GILEAD SCIENCES INC | GILD | COM | $22,520,105 | 178,250 | SH | None |
| JAZZ PHARMACEUTICALS PLC | JAZZ | SHS USD | $21,070,417 | 87,440 | SH | None |
| BIOGEN INC | BIIB | COM | $20,493,291 | 94,850 | SH | None |
| STRYKER CORPORATION | SYK | COM | $20,464,600 | 65,000 | SH | None |
| BOSTON SCIENTIFIC CORP | BSX | COM | $19,227,340 | 450,500 | SH | None |
| JOHNSON & JOHNSON | JNJ | COM | $18,412,825 | 72,500 | SH | None |
| GUARDANT HEALTH INC | GH | COM | $17,253,450 | 115,000 | SH | None |
| REGENERON PHARMACEUTICALS | REGN | COM | $17,078,761 | 27,390 | SH | None |
| GLAUKOS CORP | GKOS | COM | $16,631,440 | 119,000 | SH | None |
| BIOMARIN PHARMACEUTICAL INC | BMRN | COM | $16,622,410 | 290,500 | SH | None |
| NURIX THERAPEUTICS INC | NRIX | COM | $16,599,905 | 684,250 | SH | None |
| NATERA INC | NTRA | COM | $16,572,022 | 61,050 | SH | None |
| MIRUM PHARMACEUTICALS INC | MIRM | COM | $16,296,729 | 139,205 | SH | None |
| INSMED INC | INSM | COM PAR $.01 | $16,201,975 | 151,960 | SH | None |
| TENET HEALTHCARE CORP | THC | COM NEW | $15,939,216 | 85,200 | SH | None |
| THERMO FISHER SCIENTIFIC INC | TMO | COM | $15,832,949 | 31,580 | SH | None |
| CENTENE CORP DEL | CNC | COM | $15,662,360 | 244,000 | SH | None |
| AXSOME THERAPEUTICS INC. | AXSM | COM | $15,432,748 | 63,050 | SH | None |
| DANAHER CORPORATION | DHR | COM | $15,286,401 | 80,252 | SH | None |
| VERTEX PHARMACEUTICALS INC | VRTX | COM | $15,242,160 | 30,685 | SH | None |
| ANTERIS TECHNOLOGIES GLOBAL | AVR | COM | $15,155,456 | 1,538,625 | SH | None |
| NEUROCRINE BIOSCIENCES INC | NBIX | COM | $14,467,213 | 85,841 | SH | None |
| PENNANT GROUP INC | PNTG | COM | $13,725,853 | 371,471 | SH | None |
| INTUITIVE SURGICAL INC | ISRG | COM NEW | $13,719,960 | 34,500 | SH | None |
| ELEVANCE HEALTH INC | ELV | COM | $13,496,877 | 34,900 | SH | None |
| LIVANOVA PLC | LIVN | SHS | $13,485,720 | 164,000 | SH | None |
| CENCORA INC | COR | COM | $13,237,238 | 46,778 | SH | None |
| CHARLES RIV LABS INTL INC | CRL | COM | $12,972,388 | 57,200 | SH | None |
| IDEAYA Biosciences Inc | IDYA | COM | $12,813,426 | 343,800 | SH | None |
| MCKESSON CORP | MCK | COM | $12,505,180 | 16,550 | SH | None |
| SYNDAX PHARMACEUTICALS INC | SNDX | COM | $12,247,065 | 560,250 | SH | None |
| BRIGHTSPRING HEALTH SVCS INC | BTSG | COM | $11,569,587 | 165,896 | SH | None |
| MEDTRONIC PLC | MDT | SHS | $11,343,350 | 145,000 | SH | None |
| MINERALYS THERAPEUTICS INC | MLYS | COM | $11,233,690 | 416,371 | SH | None |
| OSCAR HEALTH INC | OSCR | CL A | $11,179,840 | 392,000 | SH | None |
| ROYALTY PHARMA PLC | RPRX | SHS CLASS A | $11,045,790 | 197,000 | SH | None |
| DEXCOM INC | DXCM | COM | $10,776,000 | 160,000 | SH | None |
| ALIGN TECHNOLOGY INC | ALGN | COM | $10,625,580 | 63,000 | SH | None |
| SPYRE THERAPEUTICS INC | SYRE | COM NEW | $10,591,454 | 119,300 | SH | None |
| RELAY THERAPEUTICS INC | RLAY | COM | $10,589,860 | 566,000 | SH | None |
| ARROWHEAD PHARMACEUTICALS IN | ARWR | COM | $10,433,280 | 128,000 | SH | None |
| AGILENT TECHNOLOGIES INC | A | COM | $9,962,250 | 75,000 | SH | None |
No matching rows. Clear the filter to see all records.
Largest 50 positions by reported value; the filing may contain more positions.
How amendments affect these holdings
This view uses 1 effective filing version(s). A restatement replaces the previous book; a new-holdings amendment adds positions. 0 positions lack a resolved ticker and 0 positions are put or call entries.
A 13F is a delayed quarterly snapshot of disclosed holdings. It is not a complete trade ledger and does not reveal every position in a manager's portfolio. Option values refer to the reported underlying position rather than a traded option premium.
Quarter end and public filing date
Use the filing's public availability date when constructing a historical observation. The quarter-end report period is earlier and cannot be substituted for when the public learned the holdings.